Ceftin (cefuroxime axetil) is a second-generation cephalosporin antibiotic indicated for the treatment of a wide range of bacterial infections. It functions by inhibiting bacterial cell wall synthesis, leading to bactericidal activity against susceptible organisms. This oral formulation offers broad-spectrum coverage, making it a versatile option in outpatient and certain inpatient settings where gram-positive and gram-negative pathogens are implicated.

Features

• Active ingredient: cefuroxime axetil
• Available in 250 mg and 500 mg film-coated tablets
• Also available as oral suspension (125 mg/5 mL or 250 mg/5 mL after reconstitution)
• Prodrug hydrolyzed to active cefuroxime after absorption
• Broad-spectrum activity covering many gram-positive and gram-negative bacteria
• Stable against many beta-lactamases

Benefits

• Effectively treats respiratory tract infections, including bronchitis and pneumonia
• Clinically proven for skin and soft tissue infections caused by susceptible Staphylococcus and Streptococcus species
• Used in the management of Lyme disease in early stages
• Provides coverage against common urogenital pathogens, including Neisseria gonorrhoeae
• Convenient twice-daily dosing regimen enhances patient compliance
• Well-established safety profile with extensive clinical use history

Common use

Ceftin is commonly prescribed for bacterial pharyngitis and tonsillitis caused by Streptococcus pyogenes. It is frequently used for acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia. Dermatologists often prescribe it for uncomplicated skin and skin structure infections, including impetigo. In urological practice, it’s employed for uncomplicated urinary tract infections. Additionally, it serves as an effective treatment for early Lyme disease and uncomplicated gonorrhea.

Dosage and direction

The recommended dosage varies based on infection type and severity. For most respiratory infections: 250-500 mg twice daily for 7-10 days. For skin and skin structure infections: 250-500 mg twice daily for 10 days. For uncomplicated urinary tract infections: 125-250 mg twice daily for 7-10 days. For early Lyme disease: 500 mg twice daily for 20 days. The tablets should be taken with food to enhance absorption. The oral suspension must be shaken well before each use and can be taken with or without food.

Precautions

Patients with renal impairment require dosage adjustment based on creatinine clearance. Use with caution in patients with history of gastrointestinal disease, particularly colitis. May result in overgrowth of nonsusceptible organisms, including fungi. Prolonged use may lead to superinfection. Caution advised in patients with history of hypersensitivity reactions to penicillins or other beta-lactam antibiotics. Monitor for signs of pseudomembranous colitis during and after treatment.

Contraindications

Known hypersensitivity to cefuroxime or other cephalosporins. Patients with history of severe immediate hypersensitivity reactions to penicillins or other beta-lactam antibiotics. Contraindicated in patients with known anaphylactic reactions to cephalosporins. Not recommended for patients with inborn errors of metabolism involving phenylalanine (tablets contain phenylalanine).

Possible side effect

Common adverse reactions include diarrhea (3-7%), nausea/vomiting (2-5%), and abdominal pain. Less frequent side effects comprise headache, dizziness, and transient elevations in liver enzymes. Rare but serious effects include pseudomembranous colitis, hypersensitivity reactions, and hematologic abnormalities. Superinfections with resistant organisms may occur. Some patients report taste perversion and vaginal candidiasis.

Drug interaction

Probenecid may inhibit renal excretion of cefuroxime, increasing serum concentrations. Antacids and H2-receptor antagonists may reduce absorption when taken concomitantly. May affect gut flora, potentially reducing efficacy of oral contraceptives—recommend alternative contraception during treatment. False positive reactions for glucose in urine may occur with copper reduction tests. No significant interaction with warfarin documented, but monitoring advised.

Missed dose

If a dose is missed, take it as soon as remembered unless it’s almost time for the next dose. Do not double the dose to make up for a missed one. Maintain regular dosing schedule. If multiple doses are missed, contact healthcare provider for guidance. Consistent dosing is important to maintain therapeutic blood levels.

Overdose

Symptoms may include nausea, vomiting, epigastric distress, and diarrhea. In cases of significant overdose, neurological reactions including convulsions may occur. Management should include gastric lavage and supportive measures. Hemodialysis may enhance elimination of cefuroxime. Serum levels can be monitored in cases of significant overdose. Contact poison control center for latest guidance.

Storage

Store tablets at room temperature (15-30°C) in original container. Keep tightly closed and protect from moisture. Oral suspension: after reconstitution, store in refrigerator (2-8°C) and discard after 10 days. Do not freeze. Keep all medications out of reach of children. Do not use after expiration date printed on packaging.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. Ceftin is a prescription medication that should only be used under supervision of a qualified healthcare professional. Individual response to medication may vary. Always follow your healthcare provider’s instructions regarding dosage and administration. Report any adverse reactions to your physician immediately.

Reviews

Clinical studies demonstrate Ceftin’s efficacy with success rates of 85-95% for approved indications. Physicians report good tolerability and patient compliance with the twice-daily regimen. Some patients note gastrointestinal discomfort, which often resolves with continued use. The broad spectrum of activity makes it particularly valuable in empirical therapy. Many practitioners appreciate its role in penicillin-allergic patients when cross-reactivity concerns are minimal.